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Interferon –Inducible Protein-10 (IP-10) and Eotaxin
as Biomarkers in Age-Related Macular Degeneration
Fong Ming Mo,1,2 Alan D. Proia,3 Walter H. Johnson,4 Desiree Cyr,1
and Kameran Lashkari1,2
PURPOSE. To analyze serum cytokine levels in subjects with
different stages of AMD and to study the expression of salient
cytokines in postmortem eyes with AMD.
METHODS. A suspension array system was used to analyze sera
(n  18 to 20/group) from control subjects and those with
early AMD (AREDS stage 1), intermediate dry AMD (AREDS
stage 3), advanced AMD with geographic atrophy (GA), or
neovascular AMD (CNV). Postmortem eyes with AMD or con-
trol eyes were examined immunohistochemically for expres-
sion of IP-10 and eotaxin (n  4 to 8/group).
RESULTS. Serum eotaxin and IP-10 levels were significantly ele-
vated in all stages of AMD, except for eotaxin levels in neovas-
cular AMD (P  0.07). The peak of serum IP-10 concentration
was at intermediate dry AMD. In donor eyes, IP-10 and eotaxin
expressions were increased in the RPE of eyes with early AMD,
GA, and CNV. Eotaxin accumulated within the layer of basal
linear/laminar deposits in all stages of AMD, while IP-10 was
mainly in eyes with GA and CNV. IP-10 was abundant in the
connective tissue matrix associated with CNV, and eotaxin was
usually present but more focally and with less intense staining.
Both IP-10 and eotaxin were expressed by neovascular endo-
thelial cells. Both IP-10 and eotaxin were expressed in the
neurosensory retina, but there was no detectable difference in
staining between eyes with or without AMD.
CONCLUSIONS. IP-10 and eotaxin may be early biomarkers in
AMD. The authors hypothesize that the relative balance be-
tween levels of IP-10 and eotaxin is critical in regulating the
neovascular response. (Invest Ophthalmol Vis Sci. 2010;51:
4226–4236) DOI:10.1167/iovs.09-3910
Age-related macular degeneration (AMD) is a chronic dis-ease that develops over decades and may lead to severely
damaged vision.1 This process is initially heralded by accumu-
lation in the aging retinal pigment epithelial (RPE) cells of
lipofuscin granules from long-term turnover and recycling of
photoreceptor outer segments2 and induction of oxidative
stress.3–5 Early phenotypic findings in AMD include the appearance
of hard and soft drusen.6 Some drusen constituents identified in
proteomic studies include proinflammatory stimuli.4,7,8 It is cur-
rently accepted that inflammation plays an important role in
the pathogenic progression of AMD.1,5,9 Thus, control of
chronic inflammation may retard the progression to the ad-
vanced form of AMD and may limit visual loss from this disease.
Chronic inflammation consists of a series of biological re-
sponses to harmful stimuli that include activation of subsets of
immune cells, which are recruited to inflamed areas, angiogen-
esis and scar formation.10,11 Inflammatory cells are regulated
by a multitude of cytokines.12,13 Inhibition of cytokine release
may affect the disease outcome.14–17 For example, mice defi-
cient in monocyte chemotactic protein (MCP)-1 or its receptor
develop cardinal features of AMD.14 Some cytokines have been
implicated in AMD, including vascular endothelial growth fac-
tor (VEGF) which supports choroidal neovascularization.18 In-
terleukin (IL)-1 and tissue necrosis factor (TNF)- are also
detected in AMD tissues.19,20 However, the systemic cytokine
profile of subjects with AMD has not been studied. Understand-
ing the cytokine profile, especially with respect to inflamma-
tion, may further elucidate the underlying pathogenic mecha-
nisms that participate in AMD.
Thus, we hypothesized that the cytokine profile in AMD is
changed in response to inflammatory signals that could be
manifested in the course of the disease and be detected in the
circulation. In this study, we screened 27 serum cytokines in
subjects with AMD and in age-matched control subjects with
no phenotype or family history of AMD. This cytokine panel
included Th-1- or -2–associated cytokines, other inflammatory
cytokines, as well as angiogenic and angiostatic factors. After
screening, we identified two serum cytokines that were signif-
icantly elevated in subjects with AMD: interferon –inducible
protein-10 (IP-10) and eotaxin. We performed statistical tests
to validate that these two cytokines could be biomarkers for
detection of the early stage of AMD. We then studied the
expression of IP-10 and eotaxin in ocular tissues from eyes
with various stages of AMD obtained at autopsy and in control
specimens.
IP-10 belongs to a group of -chemokines in which the first
two cysteine residues are separated by an intervening amino
acid (CXC) and the ELR tripeptide motif is absent.11,21 The
ELR-lacking -chemokines possess high affinity for the CXCR3
receptors found on activated T cells and natural killer (NK)
cells.11,22 IP-10 is a known chemoattractant to Th1 lympho-
cytes and monocytes. It has been considered a pathogenic
factor in cerebral malaria,23,24 multiple sclerosis,25–27 Graves’
disease,28 and proliferative glomerulonephritis.29,30 In addition
to its role in chemotaxis, IP-10 is angiostatic and antifi-
brotic.31,32 Eotaxin is a member of the cc cytokine family.11
This Th2-associated chemokine is a potent chemoattractant for
eosinophils.11,33 The pathophysiological roles for eotaxin in
gastrointestinal allergy and allergic pulmonary disease have
been reported.34–36
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MATERIALS AND METHODS
AMD and Control Subjects
This study was approved by the Institutional Review Board of the
Schepens Eye Research Institute. Seventy-eight subjects with pheno-
typic and clinical evidence of AMD were recruited into the study and
were classified according to the Age-Related Eye Disease Study
(AREDS)37 into AREDS stage 1 (early AMD), AREDS stage 3 (interme-
diate dry AMD), geographic atrophy (defined as geographic loss of
photoreceptor-RPE-choriocapillaris), and neovascular AMD that in-
cludes classic and occult lesions in active stage. All subjects were
examined by slit-lamp biomicroscopy, optical coherence tomography,
fundus photography, and fluorescein angiography (when indicated).
Eighteen age-matched subjects with no phenotype of AMD and no
family history of AMD were recruited as control subjects and were
examined by using similar methods. All subjects were given a simple
questionnaire regarding their smoking history, and whether they had
or were treated for hypertension and hypercholesterolemia. Inclusion
criteria included minimum age of 55 years and willingness to partici-
pate in the study. Subjects with the following systemic conditions were
excluded from the study: any cancer, inflammatory conditions includ-
ing collagen vascular disease, arthritis, use of nonsteroidal or steroidal
anti-inflammatory or immune-modulating agents, diabetes mellitus, kid-
ney or liver disease, vascular diseases such as stroke, blood dyscrasia,
or recent surgery (90 days). The following ocular conditions were
also excluded: history of glaucoma or suspected glaucoma, use of
topical anti-inflammatory products; history of central or branch retinal
vein occlusion, diabetic retinopathy, retinal detachment, other chronic
macular disease; and recent cataract extraction (90 days). Subjects
were asked to sign a detailed consent form, and blood samples were
obtained for plasma and serum collection. The protocols conducted in
human subjects complied with the Declaration of Helsinki.
Serum Samples Preparation and Suspension
Array Assay for Cytokine Measurement
Blood samples were allowed to clot for at least 30 minutes at room
temperature or at 4°C overnight, and then centrifuged 1000 g for 10
minutes to remove cellular components. Sera were collected and
stored at 20°C. Suspension array assay components, including the
validation kit (Bio-Plex, V4), calibration kit, and human 27-plex were
purchased from Bio-Rad Laboratories (Hercules, CA). Samples (50 L)
were diluted fourfold with human serum diluent, and the results were
adjusted for the dilution factor. Each sample was run in duplicate on
the multicytokine suspension array system (Bio-Plex; Bio-Rad), accord-
ing to the manufacturer’s protocol. The eotaxin detection antibody in
the cytokine assay recognizes eotaxin-1.
Tissue Specimens
Eyes of the patients who had died recently and were undergoing
autopsy were enucleated and fixed in 4% neutral-buffered formalde-
hyde solution, embedded in paraffin, and sectioned at Duke University
Hospital, Department of Pathology. H&E and PAS (periodic acid-Schiff
reagent) stained sections were examined by one of us (ADP) and
evaluated for subretinal lesions characteristic of AMD. Early-stage AMD
was diagnosed by the presence of confluent drusen or granular and/or
striated, eosinophilic, PAS-positive material typical of basal linear/
laminar deposit between the RPE and Bruch’s membrane. The RPE
layer and choriocapillaris remained intact although the RPE was some-
times irregular. GA was characterized by degeneration of photorecep-
tors and RPE and the presence of a transition zone. CNV exhibited the
presence of new vessels on the inner side of the Bruch’s membrane
with associated RPE and/or photoreceptor degeneration. The control
group consisted of age-matched eyes that had normal Bruch’s mem-
brane and RPE anatomy with the absence of basal deposits or confluent
drusen within the macular area. The use of the donor eyes for research
was approved by the Institutional Review Board of the Duke University
Health System and the eyes were obtained and managed in compliance
with the Declaration of Helsinki.
Immunohistochemistry
Histologic sections were heated at 60°C for 30 minutes, deparaffinized
in xylene solution, and rehydrated through a graded ethanol series. For
IP-10 staining, tissues sections were treated with a universal blocking
reagent (Background Sniper; Biocare Medical, Concord, CA), and then
were incubated with mouse monoclonal anti-human IP-10 antibody
(Santa Cruz Biotechnology, Santa Cruz, CA) at a concentration of 1.5
g/mL for 1 hour at room temperature. Slides were washed in TBS-T
(Biocare Medical) and incubated with mouse AP-polymer kit (Biocare
Medical), stained with a fast red chromogen kit (Vulcan-2; Biocare
Medical), and counterstained with hematoxylin (Vector Laboratories,
Burlingame, CA). For eotaxin staining, antigen was retrieved by incu-
bation with 0.5% pepsin in 10 mM HCl at 37°C for 10 minutes. Tissue
sections were blocked with 10% goat serum and avidin for 1 hour and
then incubated with rabbit polyclonal anti-human eotaxin antibody
(Abcam, Inc., Cambridge, MA) at a concentration of 4 g/mL for 2
hours. This antibody recognizes all three known forms of eotaxin.
Tissue sections were washed with TBS-T, incubated with biotinylated
goat anti-rabbit antibody (1:250), stained by AP-linked substrate kit
(Vector Laboratories), and counterstained with hematoxylin. Negative
control slides were treated identically except that corresponding non-
immune IgG isotype was substituted for the primary antibody.
Statistical Analysis
GraphPad Prism 4 and Prism statistics (GraphPad Software, Inc., La
Jolla, CA) were used to plot graphs and perform statistical analyses.
Since serum samples were not distributed in a Gaussian fashion, a
Mann-Whitney test was used to test the statistical difference between
the AMD and control groups. A nonparametric age-matched paired
Wilcoxon signed-rank sum test was also used to compare the signifi-
TABLE 1. Clinical Profile of Study Subjects
Control AREDS I AREDS III GA CNV
Total subjects, n 18 20 19 20 19
Men 9 6 7 6 5
Women 9 14 12 14 14
Mean age in years  SD 69  2 72  2 78  1 83  2 81  1
Smoker
No 12 15 9 11 12
Former 5 4 9 5 5
Yes 1 1 1 4 2
Hypertension
No 8 9 5 10 7
Yes 10 11 14 10 12
High cholesterol
No 11 12 12 16 11
Yes 7 8 7 4 8
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FIGURE 1. Twenty serum cytokine concentrations are represent mean and SEM. *Significant differences between control subjects and those with
each stage of AMD by the Mann-Whitney test.
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cant differences in cytokine levels between the AMD and control
groups; the result excluded age as a confounding factor.38
RESULTS
Serum Cytokines and AMD
Table 1 summarizes the clinical data of all 96 subjects. There
were between 18 and 20 subjects in each group. The distribu-
tion of smokers, hypertension, and cholesterol levels in the
study groups are indicated.
The results of the analysis of levels of 20 cytokines in these
samples are shown in Figure 1. The concentrations of five
cytokines (IL-2, IL-15, IL-17, FGF, and GM-CSF) were below 0.2
pg/mL, the lowest limit of detection for these analytes. These
cytokines were therefore regarded as undetectable. The levels
of RANTES and PDGF-bb exceeded the upper limit of the
standard curves and were excluded from the study. Of the 20
cytokines studied, only IP-10 and eotaxin were significantly
elevated in the AMD study group. These two cytokines were
selected for further study and analysis.
Serum Eotaxin and IP-10 Levels in Subjects
with AMD
The mean serum concentrations and individual distributions of
eotaxin and IP-10 are shown in Figure 2. Eotaxin was significantly
increased in AREDS stages 1 and 3 and in GA (P 0.02, 0.007,
and  0.005, respectively), but not in neovascular AMD (CNV;
P  0.07). There were no differences in eotaxin concentra-
tions among AMD subgroups.
IP-10 was increased in AREDS stage 1 (P  0.004) and
remained high in all stages of AMD. In AREDS stage 3, IP-10
levels reached a peak (P  0.002). In advanced AMD, IP-10
levels were lower in subjects with neovascular AMD than in
AREDS stage 3 and GA (P  0.05 and P  0.03, respectively).
Age-Matched Pair Analysis of IP-10 and Eotaxin in
Subjects with AMD
Subjects in the control group ranged between 59 and 85 years
of age. There was a similar wide span of ages in the four groups
of subjects with AMD. However, mean ages were higher in the
groups with more severe AMD. To illustrate, we assigned a
numeric code for the stages of AMD, with 0 assigned to no
AMD, 1 to AREDS stage 1, 3 to AREDS stage 3, 4 to neovascular
AMD, and 5 to GA (Fig. 3). The strong correlation between age
and level of AMD necessitated the use of statistical methods to
remove age as a factor when studying cytokine levels and AMD
stage. To accomplish this adjustment, age-matched groups
were formed and levels of eotaxin and IP-10 were compared
only in subjects of the same age (within 1 year). To avoid any
assumptions about normality, we used the nonparametric
matched pair Wilcoxon signed rank sum test. The null hypoth-
esis states that for subjects of the same age, the level of
cytokine (eotaxin or IP-10) is the same for control subjects and
those with any stage of AMD. Twelve age groups, each con-
taining control subjects (AMD  0) and subjects with AMD
(AMD  0) were formed, and the average cytokine level was
calculated for each age group. The difference between these
two average cytokine levels was then determined according to
the following equation:
Differencesame age  mean cytokine (AMD  0)
 mean cytokine (AMD  0).
Results of a comparison of cytokine levels in age-matched
AMD subjects and control subjects are shown in Table 2. The
FIGURE 2. Mean serum concentra-
tions and individual serum distribu-
tions of eotaxin and IP-10 are shown
for subjects with various stages of
AMD and for control individuals.
(A) Mean serum eotaxin concentra-
tion; (B) individual distribution of se-
rum eotaxin concentration; (C) mean
serum IP-10 concentration; (D) each
individual distribution of IP-10. Error
bars represent SEM; *statistically signif-
icant differences between control sub-
jects and those with each stage of
AMD (Mann-Whitney test).
FIGURE 3. The linear increase in the mean age of subjects against the
severity of AMD. Each stage of AMD was assigned a numeric code: 0,
AREDS 0 (no AMD); 1, AREDS stage 1; 2, AREDS stage 2; 3, AREDS stage
3; 4, neovascular AMD; and 5, AMD with GA. Error bars represent SEM.
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absolute values of the differences were ranked and the ranks of
the negative differences were summed. Most of the differences
among age-matched groups were positive (AMD 0 AMD
0) indicating that the level of the cytokine in any AMD category
was higher than those in the control group. Table 2A shows
the concentrations of eotaxin in control subjects (AMD 0), in
subjects with any stage AMD (AMD  0), and their respective
difference, in an age-matched manner. The Wilcoxon statistical
test38 indicates that the probability of such a distribution is
0.005. We concluded that eotaxin levels at any stage of AMD
were higher than in control subjects with no AMD.
To determine whether elevated levels of eotaxin could be
used as a biomarker for early-onset AMD (AREDS stage 1),
age-matched groups of subjects with AMD 0 were compared
with those with AMD  1. The difference between eotaxin
levels for AREDS stage 1 (AMD  1) and control (AMD  0)
was calculated according to the following formula:
Differencesame age  eotaxin (AMD  1)  eotaxin (AMD  0).
Of the 10 groups in which the age in each group was the
same (within 2 years; Table 2B), differences were dominantly
positive with the largest differences being always positive. The
Wilcoxon test shows the probability of such a distribution is
0.05. We concluded that eotaxin levels in subjects with
AREDS stage 1 AMD are significantly higher than those in
control subjects with no AMD.
A similar analysis was performed for IP-10 using the same
age-matched groups. Table 2C shows the concentrations for
IP-10 for control subjects (AMD  0), subjects with any AMD
(AMD  0), and their differences. The concentrations of IP-10
in subjects with any stage of AMD were significantly higher
than those in the control group. The Wilcoxon test shows the
probability of such a distribution is  0.025.
Table 2D shows the concentrations of IP-10 for age-
matched control subjects (AMD  0), subjects with AREDS
stage 1 (AMD  1) and their differences and shows signifi-
cantly higher IP-10 levels for subjects with stage 1 AMD than in
the control group with no AMD (P  0.025).
Immunohistochemical Localization of IP-10 and
Eotaxin in Eyes, with or without AMD
The expression of IP-10 and eotaxin in eyes obtained at au-
topsy of patients with different stages of AMD and in age-
TABLE 2. Wilcoxon Signed Rank Sum Test for Serum Eotaxin and IP-10 in Age-Matched Subject Pairs
Mean Concentrations of Eotaxin
A. Comparison of Mean Eotaxin Concentrations in Control
Group and in Subjects with AMD
B. Comparison of Mean Eotaxin Concentrations in Control
Group and in Subjects with Stage 1 AMD
Age
Group (y)
Control
Group
(AMD  0)
Subjects
with AMD
(AMD > 0)
Difference
(AMD > 0  AMD  0)
Age
Group (y)
Control
Group
(AMD  0)
Subjects with
Stage 1 AMD
(AMD  1)
Difference
(AMD  1  AMD  0)
58–59 13.7 93.3 79.6 58–59 13.7 93.3 79.6
60 45.8 202.4 156.5 60–62 98.9 86.6 12.3
62 152.0 121.0 31.0 65 95.0 129.8 34.8
65 95.0 129.8 34.8 67–69 73.4 46.0 27.4
67 61.4 241.6 180.2 70 72.4 267.9 195.5
68–69 97.4 119.7 22.3 72 45.2 151.8 106.5
70 72.4 177.0 104.5 73–74 25.2 260.0 234.8
72 45.2 151.8 106.5 80 74.7 49.6 25.1
74 25.2 71.2 46.0 83 92.9 34.4 58.5
80 74.7 129.1 54.4 85 64.5 543.0 478.6
83 92.9 126.6 33.8
85 64.5 183.8 119.3
P  0.005 P  0.05
Mean Concentrations of IP-10
C. Comparison of Mean IP-10 Concentrations in Control
Group and in Subjects with AMD
D. Comparison of Mean IP-10 Concentrations in Control Group
and in Subjects with Stage 1 AMD
Age
Group (y)
IP-10
(AMD  0)
IP-10
(AMD > 0)
Difference
(AMD > 0  AMD  0)
Age
Group (y)
IP-10
(AMD  0)
IP-10
(AMD > 0)
Difference
(AMD  1  AMD  0)
58–59 166.9 527.6 360.7 58–59 166.9 529.6 360.7
60 264.6 432.0 167.4 60–62 385.2 86.6 220
62 505.8 791.8 286.0 65 808.2 1029.4 221.2
65 808.2 1029.4 221.2 67–69 514.6 753.4 238.8
67 676.9 509.0 167.8 70 1228.0 657.1 570.9
68–69 190.2 717.0 526.8 72 355.6 564.7 209.1
70 1228.0 463.3 764.7 73–74 254.3 3600.0 3345.7
72 355.6 564.7 209.1 80 404.5 1429.1 1024.6
74 254.3 4510 196.7 83 455.1 1558.0 1102.8
80 404.5 1405.4 1001.0 85 261.9 893.4 631.5
83 455.1 1007.6 552.5
85 261.9 1563.8 1301.9
P  0.025 P  0.025
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matched non-AMD control eyes was determined with immu-
nohistochemical staining. Staining intensity was graded on a
scale of 0 to 3: 0, no expression; 1, very faint staining (visible
only at high magnification); 2, moderate staining (easily visible
at intermediate magnification); 3, strong staining (visible at low
magnification). Results in all the eyes are presented in Table 3
(IP-10 scores) and Table 4 (eotaxin scores). Staining intensity
was scored by two investigators (FMM, ADP), and the results
are a consensus of their observations.
Both IP-10 and eotaxin were expressed in the neurosensory
retina in the nerve fiber layer, ganglion cell layer (GCL), inner
nuclear layer (INL), outer nuclear layer (ONL), and photore-
ceptor outer segments (POS); staining intensity was variable
among the eyes within each group, and there was no consis-
tent difference in staining among the eyes with or without
AMD, as shown in Tables 3 and 4 and Figures 4 and 5. For all
eyes, we performed negative controls for IP-10 and eotaxin
using nonimmune IgG isotype in place of the primary antibody.
The negative control slides uniformly lacked stain (results not
shown).
Despite the variation in staining intensity for IP-10 among
eyes within each group, there were definite differences in
IP-10 expression in control eyes and in those with AMD. As
shown in Figure 4, there was enhanced expression of IP-10 in
the RPE of eyes with early AMD, GA, and CNV. IP-10 accumu-
lated focally within the layer of basal linear/laminar deposit in
GA and CNV, and it was uniformly and strongly expressed by
neovascular endothelial cells and within the connective tissue
matrix associated with the CNV.
There was also variation in staining intensity for eotaxin
among eyes within each group, but again, there were distinct
differences in eotaxin expression in control and AMD eyes.
Figure 5 illustrates enhanced expression of eotaxin in the RPE
of eyes with early AMD, GA, and CNV. There was accumulation
of eotaxin within the basal linear/laminar deposit in all stages of
AMD, though the staining was patchy (focal) and less than
that observed for IP-10. Similar to our results for IP-10, we
consistently observed eotaxin expression by neovascular
endothelial cells. There was often eotaxin within the con-
nective tissue matrix associated with CNV, but the expres-
sion of eotaxin was more focal and the staining less intense
than for IP-10 in this tissue compartment (for example,
compare the staining for IP-10 in Fig. 4H with that for
eotaxin in Fig. 5H).
DISCUSSION
AMD has been proposed as an inflammatory disease.5 Our
findings implicate IP-10 and eotaxin as two inflammatory cyto-
TABLE 3. Distribution of IP-10 in the Macular and Subjacent Choroid
Case NFL GCL IPL INL OPL ONL POS RPE BLD Choroid EC Ch. Stroma
Control
1 2 2 1 0 1 1 3 0 0 1
2 1 2 0 0 1 0 2 Focal 1 0 1
3 2 2 1 Focal 1 0 0 3 Focal 2 Focal 1 Focal 1
4 2 3 2 1 1 0 2 0 1 2
5 Focal 2–3 3 1 1 1 1 3 Focal 2–3 1 2
6 1 2 1 0 1 0 1 Focal 1–2 0 0
7 0 3 1 1, Focal 2 0 Focal 1 2 0 0 2
8 1 3 1 1 0 1 2 Focal 1–2 0 Focal 1
Early AMD
11 2 3 2 1 1 1 3 3 0 2 3
12 2 3 1 Focal 0–1 0 1 2 Focal 3 Focal 2 0 Focal 1
13 3 3 2 0 1 1 3 Focal 2 0 0 2
14 2 3 1 1 0 0 2 2 0 0 1
15 2 3 2 1 2 1 3 2 0 1–2 2
16 1 3 2 2 2 1 3 1 0 1 1
17 2 3 2 1 2 2 2 3, Focal 4 Focal 1 0 1
18 2 3 1 Focal 1–2 1 1 2 Focal 1 0 0 2
GA
21 2 2 1 0 0 0 — 1 0 0 2
22 2 3 2 1 0 — — 2 Focal 1–2 0 0
23 2 3 2 1 1 1 3 3 Focal 3 1 1
24 2 3 2 1 2 0 3 2 Focal 3 Focal 1 1
Case NFL GCL IPL INL OPL ONL POS RPE Outside RPE CNV Area BLD Choroid EC Neovasc EC Ch. Stroma
CNV
27 1 3 2 1 2 1 3 3 Focal 2 Focal 3 1 2 1–2
28 3 3 1 2 2 Focal 1–2 2 3, Focal 4 Focal 1–2 Focal 2 1 3 2
29 3 3 1 1 1 1 3 3 Focal 1–2 Focal 3 1 3–4 2
30 2 3 1 1 1 Focal 1 1 2–3 Focal 2–3 2 1 2 2
31 1 2 1 1 1 Focal 1 2 1 Focal 3 1, Focal 3 1 3 3
32 2 3 1 1 0 Focal 1 2 1, Focal 2 1, Focal 2 Focal 3 1 2, Focal 3 1
Grading scale for the expression of IP-10 in the macula and subjacent choroid. 0, no expression; 1, very faint expression; 2, moderate staining;
3, strong staining; Focal, focal expression; NFL, nerve fiber layer; IPL, inner plexiform layer; OPL, outer plexiform layer; BLD, basal linear/laminar
deposits; Choroid EC, choroidal endothelial cells; Ch. stroma, choroidal stromal cells; Neovasc EC, neovascular endothelial cells; RPE outside, RPE
cells outside the area of choroidal neovascularization; RPE CNV area, RPE cells within the area of choroidal neovascularization.
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kines that are associated with the pathogenesis of AMD. The
serum level of both cytokines was increased significantly in
subjects with AMD, and both were overexpressed in histologic
sections of postmortem eyes with AMD.
In the early stage of AMD, IP-10 serum levels were increased
significantly (Fig. 1). Histologic sections of eyes with early
AMD exhibited increased immunoreactivity for IP-10 in the
RPE (Fig. 4D), and some eyes had focal staining within the
basal linear/laminar deposit. Of interest, the peak serum IP-10
concentration was detected at AREDS stage 3, remained high in
GA, and decreased slightly in the subjects with CNV (P  0.03
when compared to the peak level). Other inflammatory dis-
eases, such as Graves’ disease,28 type 1 diabetes mellitus,39
graft rejection,40 and cerebral malaria,23 exhibit high levels of
IP-10 in the circulation and in local tissues during the initial and
developing phases of the immune response. In some of these
diseases, IP-10 has been implicated as a pathogenic factor that
mediates Th-1 type inflammation by acting to recruit a subset
of leukocytes and promote their subsequent migration into the
tissue. In eyes, the potential role of IP-10 is intriguing since the
eye is considered an area of immune privilege.41 Elevated
circulating levels of IP-10 may be derived from activated lym-
phocytes as well as by the resident cells.28 In tissues of eyes
with AMD, leukocytes have been identified in the choroid
beneath the area where drusen accumulate, suggesting that
there is trafficking of a specific subset of immune cells.42
Double staining of ocular tissues with AMD indicates that
CD45 cells resembling leukocytes in the choroid also express
IP-10 (FMM, KL, unpublished observation, 2009), and thus may
represent a source of the IP-10.
The immunoreactivity of IP-10 in the macular RPE of control
eyes was absent or present focally and usually with a low
staining intensity (Fig. 4B, Table 3). In eyes with early AMD,
GA, and CNV there was increased expression of IP-10 in RPE
cells. Eyes with GA and CNV had loss of RPE in the center of
the lesions, but residual RPE cells expressed IP-10 with more
intense staining than that in control eyes. RPE cells play a
critical role in the blood–retinal barrier and in the maintenance
of the photoreceptor.1 As RPE cells age or are subjected to
oxidative stress, their expression profile of cytokines is altered
and they may upregulate proinflammatory or proangiogenic
cytokines such as VEGF, basic fibroblast growth factor-2, and
interleukin-8 for wound-healing or other pathologic func-
tions.43–46 The ability of IP-10 to antagonize the angiogenic
effect of VEGF may be particularly important in the pathogen-
esis of CNV. RPE-derived soluble VEGF is essential in the
maintenance of the choriocapillaris.47 In vitro and in vivo
studies show that VEGF can induce overexpression of IP-10 in
endothelial cells,48 but whether this may occur with the RPE is
unknown. Endothelial cells within the choroidal neovascular
membrane and the connective tissue matrix associated with
the CNV had strong expression of IP-10 (Fig. 4H), which is
intriguing, since IP-10 is well-known for its angiostatic and
antifibrotic activity.31,32 It inhibits endothelial cell proliferation
by competing with the cells for the binding sites of heparan
sulfate proteoglycans, resulting in attenuation of new vessel
TABLE 4. Distribution of Eotaxin in the Macular and Subjacent Choroid
Case NFL GCL IPL INL OPL ONL POS RPE BLD Choroid EC Ch. Stroma
Control
1 3 3 1 1 2 1 1 0 1 2
2 3 3 1 1 2 1 2 0 Focal 1 2
4 0 3 1 1 1 1 3 1 2
6 0 2 0 1 0 0 2 0 2
7 0 3 1 1, Focal 2 0 1 2 0 1–2 1
8 0 1 0 1 0 0 0 0 0 0
9 1 2 1 Focal 1 1 Focal 1 1 0 1 1
10 1 2 0 1 0 1 3 1 1
Early AMD
12 0 2 0 1 0 1 0 Focal 1 Focal 2 1 2
13 0 3 1 2 1 1 3 2 3 2 2
14 0 0 0 0 0 0 0 0 3 1 0
16 0 3 0 1 0 0 3 3 Focal 1 2 2
19 0 3 1 2 1 0 3 2 3 2 1
20 0 3 1 2 2 2 3 2 3 2 2
GA
22 2 2 0 1 1 1 3 1 Focal 2 2 2
24 0 3 0 2 0 1 3 3 Focal 3 2 2
25 0 1 0 0 0 0 0 1 Focal 2 1 1
26 0 0 0 0 0 0 0 0 1–2 0 0
Case NFL GCL IPL INL OPL ONL POS RPE Outside RPE CNV Area BLD Choroid EC Neovasc EC Ch. Stroma
CNV
27 0 1 0 1 0 0 0 1 Focal 3 0 Focal 2 2 0
29 2 3 1 2 2 3 3 2, Focal 3 1 0 2, Focal 3 3 2
30 0 3 2 2 1 2, Focal 3 3 1, Focal 2 1, Focal 2 Focal 1 2 3 2
31 3 3 1 2 1 Focal 3 2 2 3 1, Focal 2 2–3 3 2
32 1 3 1 2 1 2, Focal 3 2 2 2, Focal 3 2, Focal 3 1, Focal 2–3 3 2
33 0 3 2 2 1 1, Focal 3 3 2 2 Focal 2 2, Focal 3 3 2
34 1 3 1 2 2 1, Focal 3 3 2 2 Focal 1 1 2, Focal 3 1
See the footnote to Table 3 for an explanation of the data and abbreviations that have not been used in the text.
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formation.49,50 Based on these reports, we speculate that the
IP-10 we observed within the neovascular membrane may be
an important mechanism for dampening the effects of angio-
genic and fibrotic cytokines released during development of
CNV.
Eotaxin was reported recently to be expressed in surgically
excised choroidal neovascular tissue, as was its receptor
CCR3.51 It was present in blood vessels and stromal cells in the
excised neovascular tissues,51 similar to our observations in
donor eyes with CNV. In our study, eyes with early AMD and
GA had increased expression of eotaxin by RPE cells and
accumulation of eotaxin within basal linear/laminar deposits.
We also observed constitutive expression of eotaxin in the
neurosensory retina and stromal cells in the choroid. Eotaxin
can be secreted by endothelial cells, smooth muscle cells,52
fibroblasts,53 bronchial epithelial cells, and inflammatory cells,
such as macrophages and eosinophils.54 Our study expands the
list of tissue sources of eotaxin to include cells of the neuro-
sensory retina and choroid. The angiogenic character of
eotaxin was first proposed in 2001,55 and a study by Takeda et
al.51 showed that CCR3 blockade was effective at reducing
CNV in a mouse model. Takeda et al. concluded that eotaxin
and its receptor are important contributors to neovasculariza-
tion in association with AMD, and our results support this
hypothesis.
In addition to searching for cytokines with potential
pathogenic relevance in AMD, a second purpose of our
study was to determine whether serum cytokine levels
could serve as biomarkers to predict the early onset of AMD.
Only serum IP-10 and eotaxin concentrations were signifi-
cantly increased in subjects with AMD. Elevation of serum
IP-10 has been proposed as a biomarker to predict the
outcome in many human diseases such as severe acute
respiratory distress syndrome,56 coronary artery disease, es-
pecially in patients with restenosis,57 and as a risk factor for
renal allograft failure.58 Serum eotaxin also increased in
asthma,59 in obesity,60 and in a subgroup of hemorrhagic
shock patients with multiple organ failure.61 Eotaxin release
may be stimulated in inflamed tissues, such as in allergic
airway inflammation33 and interstitial nephritis.62 Interleu-
FIGURE 4. Immunohistochemical lo-
calization of IP-10 in postmortem
eyes with various stages of AMD and
in age-matched control eyes without
AMD. IP-10 was detected using an
alkaline phosphatase reagent. The
tissue was counterstained with he-
matoxylin and the nuclei are blue.
IP-10 was expressed in the neurosen-
sory retina in the nerve fiber layer,
GCL, INL, ONL, and photoreceptor
outer segments; there was no consis-
tent difference in staining among the
eyes without (A, B) or with AMD (C,
E, G). There was enhanced expres-
sion of IP-10 in the RPE of eyes with
early AMD (D), GA (F), and CNV (H).
IP-10 accumulated focally within the
layer of basal linear/laminar deposit
in GA (F) and CNV (H), and it was
uniformly and strongly expressed by
neovascular endothelial cells and
within the connective tissue matrix
associated with the CNV (H). Scale
bar, 50 m.
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kin (IL)-6 was not elevated in our cohort. Seddon et al.63
have reported elevated IL-6 levels in subjects with progres-
sion of AMD. Another large population cohort study by
Klein et al.64 found the elevation of IL-6 is in association only
with geographic atrophy but not with early AMD or neovas-
cular AMD. We cannot explain the reason for the difference.
The disparity may be due to the different criteria in subject
selection. We excluded all subjects who had cardiovascular
disease other than hypertension. IL-6 has been proposed as
a biomarker for cardiovascular and cerebrovascular dis-
ease65 and in the study by Seddon et al.,63 subjects with
cardiovascular disease were included. Future controlled
studies are needed to explore the association between IL-6
in AMD.
In our study, aging correlated significantly with progression
of AMD (Fig. 3), and serum IP-10 level has been reported to
increase in aging.66 We therefore performed age-matched
paired-comparison studies to exclude age as a factor in the
elevation of IP-10 in the subjects with AMD. Both IP-10 and
eotaxin were significantly elevated in subjects with AREDS
stage 1 compared with the control group. Our results raise the
possibility that serum levels of IP-10 and eotaxin may serve as
biomarkers for early AMD, when vision is unaffected and be-
fore the appearance of any significant phenotypic changes in
the retina. However, a larger study is needed to validate serum
IP-10 and eotaxin as biomarkers for early AMD. Such a study
will be useful since early diagnosis will become increasingly
important as new agents are discovered that will retard the
progression of dry AMD.
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FIGURE 5. Immunohistochemical lo-
calization of eotaxin in postmortem
eyes with various stages of AMD and
in age-matched controls without
AMD. Eotaxin was detected using an
alkaline phosphatase reagent; tissue
was counterstained with hematoxy-
lin and the nuclei are blue. Eotaxin
was expressed in the neurosensory
retina in the nerve fiber layer, GCL,
INL, ONL, and photoreceptor outer
segments; there was no consistent
difference in staining among the
eyes without (A, B) or with AMD (C,
E, and G). There was enhanced ex-
pression of eotaxin in the RPE of
eyes with early AMD (D), GA (F),
and CNV (H). Eotaxin accumulated
within the basal linear/laminar de-
posit in all stages of AMD, though
the staining was often patchy (focal).
Eotaxin was expressed by neovascu-
lar endothelial cells and it was often
present within the connective tissue
matrix associated with CNV (H).
Scale bars, 50 m.
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